NASDAQ:REPLReplimune Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.17 +0.20 (+1.82 %) (As of 04/7/2020 04:00 PM ET) Add Compare Share Today's Range$10.69Now: $11.17▼$11.3450-Day Range$8.90MA: $12.55▼$17.0952-Week Range$8.58Now: $11.17▼$19.66Volume89,300 shsAverage Volume102,840 shsMarket Capitalization$409.34 millionP/E RatioN/ADividend YieldN/ABeta2.61 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.10, Replimune Group has a potential upside of 115.8% from its current price of $11.17.Amount of Analyst CoverageReplimune Group has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesReplimune Group has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReplimune Group has received 130 “underperform” votes. (Add your “underperform” vote.)Community SentimentReplimune Group has received 55.08% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote “Outperform” if you believe REPL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have not sold or bought any company stock.Percentage Held by Insiders63.18% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.10% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow by 19.11% in the coming year, from ($1.57) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.replimune.com/ Phone781-222-9600Debt Debt-to-Equity Ratio0.20 Current Ratio13.43 Quick Ratio13.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.36 per share Price / Book2.56Profitability EPS (Most Recent Fiscal Year)($1.33) Net Income$-30,830,000.00 Net MarginsN/A Return on Equity-29.68% Return on Assets-24.86%Miscellaneous Employees62 Outstanding Shares36,646,000Market Cap$409.34 million Next Earnings Date6/26/2020 (Estimated) OptionableNot Optionable Receive REPL News and Ratings via Email Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:REPL Rates by TradingView Replimune Group (NASDAQ:REPL) Frequently Asked Questions How has Replimune Group's stock been impacted by COVID-19 (Coronavirus)? Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have decreased by 6.4% and is now trading at $11.17. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Replimune Group? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group. When is Replimune Group's next earnings date? Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Replimune Group. How were Replimune Group's earnings last quarter? Replimune Group Inc (NASDAQ:REPL) posted its quarterly earnings results on Thursday, February, 13th. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.10. View Replimune Group's earnings history. What price target have analysts set for REPL? 5 Wall Street analysts have issued 1-year target prices for Replimune Group's shares. Their forecasts range from $12.50 to $30.00. On average, they expect Replimune Group's share price to reach $24.10 in the next year. This suggests a possible upside of 115.8% from the stock's current price. View analysts' price targets for Replimune Group. What are Wall Street analysts saying about Replimune Group stock? Here are some recent quotes from research analysts about Replimune Group stock: 1. According to Zacks Investment Research, "Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. " (2/20/2020) 2. Chardan Capital analysts commented, "We expect the 4Q19 data from the phase I portion, potentially at the Cancer (SITC) annual meeting in November, will focus on safety and early signals of immune activity of RP1 as a single agent and in the combo setting. Per management, the company plans to accumulate data from the phase II cohorts over the next ~6 months and begin reporting on a per cohort basis over 2020 (consistent with prior timelines). RP1 trial, a registration-directed randomized controlled study in cutaneous squamous cell carcinoma (CSCC) +/- Regeneron’s (unrated) anti-PD1 cemiplimab is expected to begin in August. Replimune ended the quarter with $120.8 mm in cash, cash equivalents and short-term investments. This provides the company with a cash runway into calendar year 2H21." (8/15/2019) Has Replimune Group been receiving favorable news coverage? Media coverage about REPL stock has been trending very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Replimune Group earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutReplimune Group. Are investors shorting Replimune Group? Replimune Group saw a decline in short interest in February. As of February 28th, there was short interest totaling 685,300 shares, a decline of 5.8% from the February 13th total of 727,600 shares. Based on an average daily volume of 118,200 shares, the short-interest ratio is presently 5.8 days. Currently, 5.0% of the shares of the company are short sold. View Replimune Group's Current Options Chain. Who are some of Replimune Group's key competitors? Some companies that are related to Replimune Group include Bill.com (RVMD), Editas Medicine (EDIT), Regenxbio (RGNX), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Cortexyme (CRTX), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), I-Mab (BDTX), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO), Novavax (NVAX), Orchard Therapeutics (ORTX), Adverum Biotechnologies (ADVM) and Passage Bio (PASG). What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Amarin (AMRN), Fate Therapeutics (FATE), Dell (DELL), Energy Transfer LP Unit (ET), Pfizer (PFE), Exxon Mobil (XOM) and Axsome Therapeutics (AXSM). Who are Replimune Group's key executives? Replimune Group's management team includes the following people: Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)Dr. Robert Coffin, Pres, CEO & Director (Age 54)Dr. Colin Love, Chief Operating Officer (Age 61)Dr. Pamela Esposito, Chief Bus. Officer (Age 45)Stephen Gorgol, Chief Accounting Officer When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." How do I buy shares of Replimune Group? Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $11.17. How big of a company is Replimune Group? Replimune Group has a market capitalization of $409.34 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe. View additional information about Replimune Group. What is Replimune Group's official website? The official website for Replimune Group is http://www.replimune.com/. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What does an equal weight rating mean?
